6
Dec
2021
Targeted Small Molecule Protein Degraders: Nello Mainolfi on The Long Run
Today’s guest on The Long Run is Nello Mainolfi. Nello is the president and CEO of Cambridge, Mass.-based Kymera Therapeutics. Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of... Read More